Novavax vs Sinovac Biotech
NVAX and SVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NVAX and SVA compare
Sinovac Biotech grew revenue faster over the last twelve months (6.8% versus −61.3% for Novavax).
Sinovac Biotech scores higher on the StockData Score (6 against 5 for Novavax), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NVAX | SVA |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | – |
| Share price | $8.53 | $6.47 |
| Change, 1 year | 18.4% | 0.00% |
| Change, 5 years | −95.6% | 0.00% |
| Beta (5Y) | 1.92 | 0.00 |
| Employees | 749 | 2,602 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.4× | – |
| Growth | ||
| Revenue growth (TTM) | −61.3% | 6.8% (better) |
| Revenue growth, 5Y average | 18.8% (better) | −5.4% |
| Net income growth (TTM) | −122% | – |
| EPS growth (TTM) | −127% (better) | −165% |
| Profitability | ||
| Gross margin | 78.0% (better) | 67.9% |
| Operating margin | −21.2% (better) | −127% |
| Net margin | −18.6% | – |
| FCF margin | – | −145% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −4.0× | – |
| Current ratio | 2.15 | 4.59 (better) |
| Altman Z-score | −5.94 | – |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 71.2% | 14.6% |
| Held by insiders | 9.2% | 65.7% |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 30.9% | 0.33% |
Go deeper
- NVAX stock overview
- NVAX income statement
- NVAX valuation and score
- SVA stock overview
- SVA income statement
- SVA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.